Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.
Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M. Farmer P, et al. Among authors: macgrogan g. Nat Med. 2009 Jan;15(1):68-74. doi: 10.1038/nm.1908. Epub 2009 Jan 4. Nat Med. 2009. PMID: 19122658
Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer.
Chatzipli A, Bonnefoi H, MacGrogan G, Sentis J, Cameron D, Poncet C; EORTC 10994/BIG 1-00 Consortium; Iggo R. Chatzipli A, et al. Among authors: macgrogan g. Br J Cancer. 2021 Nov;125(10):1356-1364. doi: 10.1038/s41416-021-01526-3. Epub 2021 Sep 3. Br J Cancer. 2021. PMID: 34480095 Free PMC article. Clinical Trial.
Identification of molecular apocrine breast tumours by microarray analysis.
Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Farmer P, et al. Among authors: macgrogan g. Oncogene. 2005 Jul 7;24(29):4660-71. doi: 10.1038/sj.onc.1208561. Oncogene. 2005. PMID: 15897907 Free article.
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmström P, Werutsky G, Bogaerts J, Bergh J, Cameron DA; EORTC 10994/BIG 1-00 Study investigators. Bonnefoi H, et al. Among authors: macgrogan g. Ann Oncol. 2014 Jun;25(6):1128-36. doi: 10.1093/annonc/mdu118. Epub 2014 Mar 11. Ann Oncol. 2014. PMID: 24618153 Free PMC article. Clinical Trial.
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.
Bonnefoi H, MacGrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Bécette V, Kerdraon O, Bibeau F, Ghnassia JP, Picquenot JM, Thomas J, Tille JC, Slaets L, Bodmer A, Bergh J, Cameron D; EORTC 10994/BIG 1-00 study investigators. Bonnefoi H, et al. Among authors: macgrogan g. Br J Cancer. 2019 Apr;120(9):913-921. doi: 10.1038/s41416-019-0420-y. Epub 2019 Mar 22. Br J Cancer. 2019. PMID: 30899086 Free PMC article. Clinical Trial.
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
Lerebours F, Pulido M, Fourme E, Debled M, Becette V, Bonnefoi H, Rivera S, MacGrogan G, Mouret-Reynier MA, de Lara CT, Pierga JY, Breton-Callu C, Venat-Bouvet L, Mathoulin-Pélissier S, de la Motte Rouge T, Dalenc F, Sigal B, Bachelot T, Lemonnier J, Quenel-Tueux N. Lerebours F, et al. Among authors: macgrogan g. Br J Cancer. 2020 Mar;122(6):759-765. doi: 10.1038/s41416-020-0733-x. Epub 2020 Jan 31. Br J Cancer. 2020. PMID: 32001832 Free PMC article. Clinical Trial.
Endocrine-responsive breast cancer special types: who cares?
Bonnefoi H, MacGrogan G. Bonnefoi H, et al. Among authors: macgrogan g. Ann Oncol. 2012 Jun;23(6):1375-7. doi: 10.1093/annonc/mds131. Epub 2012 Apr 29. Ann Oncol. 2012. PMID: 22547540 Free article. No abstract available.
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, Shepherd L, Amaral N, Duval C, Drijkoningen R, Larsimont D, Piccart M. Bonnefoi H, et al. Among authors: macgrogan g. Ann Oncol. 2003 Mar;14(3):406-13. doi: 10.1093/annonc/mdg108. Ann Oncol. 2003. PMID: 12598346 Free article. Clinical Trial.
223 results